News release from UNC-Chapel Hill Cancer Center on a recently published joint paper with Lipomedix on our product Promitil and radiotherapy (

On May 2016 Lipomedix received a 2million shekel grant from the Israel Chief Scientist Office for the funding of the project “Development of Promitil a pegylated liposomal MMC- prodrug”


Publications and presentations:

Poster entitled “A Phase 1B Study of Pegylated Liposomal Mitomycin-C Prodrug with or without Capecitabine and Bevacizumab in Third Line Chemotherapy of Colorectal Cancer” at the ESMO meeting, October 10-13, 2016, Copenhagen, Denmark

Poster entitled “A Multidrug Formulation of Pegylated Liposomes with Co-Encapsulated Alendronate, Doxorubicin, and Mitomycin-C Lipid–Based Prodrug for Chemo-Immunotherapy of Cancer at the ICRS meeting, September 14-16, 2016, Maalot, Israel



Lipomedix is seeking additional funding from private investors or investment groups for clinical studies leading to registration of Promitil® in US and world markets for advanced metastatic colo-rectal cancer, and for further developing its pipeline. Prospective investors are invited to meet with the Company’s management team to discuss an investment in the Company.